Adherex Technologies Inc.

Adherex Technologies Inc.

November 09, 2006 08:30 ET

Preclinical Data on Adherex's ADH-1 in Combination With Chemotherapy Presented at 18th EORTC-NCI-AACR Symposium Conference in Prague

Eniluracil and ADH-1 clinical data to be presented at Chemotherapy Foundation Symposium in New York

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - Nov. 9, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that preclinical data on ADH-1 in combination with chemotherapy was presented today during a poster session at the 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" at the Prague Congress Centre, Prague, Czech Republic. The poster, entitled "Inhibition of N-cadherin enhances anti-tumor activity and overcomes chemoresistance in regional melanoma therapy," was authored by C.K. Augustine1,3, Y. Yoshimoto1,3, P. Zipfel1,3, M.A. Selim2, and D.S. Tyler1,3, and will be made available on the Adherex website at The poster summarizes the unexpected and synergistic effects observed in the preclinical studies conducted at Duke using ADH-1 in combination with regional melanoma chemotherapy.

The Company also announced that updated data on the Phase I trial of eniluracil + 5-FU in solid tumors as well as the Phase I single agent trials of ADH-1 will be presented on Friday, November 10, 2006 at the Chemotherapy Foundation Symposium XXIV: "Innovative Cancer Therapy for Tomorrow" in New York City; the former will be presented by Dr. Howard A. Burris, Director of Drug Development, Sarah Cannon Research Center, and the latter by Dr. William P. Peters, Adherex's Chairman and CEO. These data were presented at the Adherex Analyst and Investor Meeting on November 8, 2006, a webcast of which is available for viewing at

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at

This press release may contain forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. We are subject to various risks, including the uncertainties of clinical trials, drug development and regulatory review, our need for additional capital to fund our operations, ,our reliance on collaborative partners, the early stage of our product candidates, our history of losses, and other risks inherent in the biopharmaceutical industry. For a more detailed discussion of related risk factors, please refer to our public filings available at and

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484